General Information of Drug (ID: DMOJEXG)

Drug Name
CART-Muc1 cells Drug Info
Indication
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Phase 1 [1]
Myelodysplastic syndrome 2A37 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMOJEXG

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug(s) Targeting Mucin-1 (MUC1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Yttrium (90Y) clivatuzumab tetraxetan DMOLR5W Pancreatic cancer 2C10 Phase 3 [2]
TG-4010 DMWE3GB Bipolar disorder 6A60 Phase 2/3 [3]
ICO-25 DMC13BQ Breast cancer 2C60-2C65 Phase 2 [4]
MUC1-Poly-ICLC DML7N4B Colorectal cancer 2B91.Z Phase 2 [5]
AS-1402 DMMX1EJ Breast cancer 2C60-2C65 Phase 2 [6]
Emepepimut-S DMCLT2F Non-small-cell lung cancer 2C25.Y Phase 2 [7]
GO-203-2c DMLWKZ7 Acute myeloid leukaemia 2A60 Phase 2 [8]
SAR-566658 DMT4FI5 Triple negative breast cancer 2C60-2C65 Phase 2 [9]
Pankomab-GEX DMAZ460 Solid tumour/cancer 2A00-2F9Z Phase 2 [10]
ImMucin DM09JOZ Multiple myeloma 2A83 Phase 1/2 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Mucin-1 (MUC1) TTBHFYQ MUC1_HUMAN CAR-T-Cell-Therapy [1]

References

1 ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS
2 Clinical pipeline report, company report or official report of Immunomedics.
3 A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer. J Thorac Oncol. 2008 Jul;3(7):735-44.
4 The role of epithelial antigens in diagnosis and staging of breast cancer. Arkh Patol. 2002 Nov-Dec;64(6):13-5.
5 Early in vivo signaling profiles in MUC1-specific CD4+ T cells responding to two different MUC1-targeting vaccines in two different microenvironments. Oncoimmunology. 2013 Mar 1;2(3):e23429.
6 Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer. Breast Cancer Res. 2009;11(5):R73.
7 Emepepimut-S for non-small cell lung cancer. Expert Opin Biol Ther. 2011 Aug;11(8):1091-7.
8 Clinical pipeline report, company report or official report of Genus Oncology.
9 Integrating in vitro signaling and drug response data from single cell network profiling (SCNP) to inform on individual's AML biology.Molecular Cancer Therapeutics. 11/2011; 10(Supplement 1):A73-A73.
10 Staining of MUC1 in ovarian cancer tissues with PankoMab-GEX detecting the tumour-associated epitope, TA-MUC1, as compared to antibodies HMFG-1 and 115D8. Histol Histopathol. 2013 Feb;28(2):239-44.
11 Phase I/II study exploring ImMucin, a pan-major histocompatibility complex, anti-MUC1 signal peptide vaccine, in multiple myeloma patients. Br J Haematol. 2015 Apr;169(1):44-56.